Condition: Insomnia · Psychiatric Disorders · Sponsor: Shanghai Mental Health Center
This study aims to evaluate the effectiveness and safety of lemborexant (a new dual orexin receptor antagonist) in the treatment of patients with mental disorders complicated with insomnia. The subjects are patients aged 18 years and above, who meet the DSM-5 diagnostic criteria for mental disorders and have an Insomnia Severity Index (ISI) score ≥11. They will receive lemborexant treatment for 8 weeks, with follow-up to observe the improvement of insomnia symptoms and adverse events, so as to provide real-world evidence for the clinical optimization of treatment regimens for insomnia comorbid with psychiatric disorders.
This description comes directly from the study's public registry record.
Wenzheng Wang, PhD · 18017311500 · fffty@163.com
Always discuss trial participation with your own doctor first.
| Suzhou GuangJi Hospital | Suzhou, Jiangsu, China | Recruiting |
| Xuzhou Oriental People's Hospital | Xuzhou, Jiangsu, China | Recruiting |
| Shanghai Mental Health Center | Shanghai, Shanghai Municipality, China | Recruiting |
| Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai Pudong New Area Mental Health Center | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai Fengxian District Mental Health Center | Shanghai, Shanghai Municipality, China | Recruiting |
| Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| The Second Affiliated Hospital of Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| The First Affiliated Hospital of Ningbo University | Ningbo, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07417813